NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Wednesday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO opened at $3.69 on Wednesday. The stock’s 50 day moving average price is $3.68 and its 200-day moving average price is $3.88. NeuroMetrix has a 52-week low of $2.70 and a 52-week high of $12.04. The stock has a market capitalization of $7.34 million, a PE ratio of -0.59 and a beta of 2.26.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings data on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. The company had revenue of $1.32 million during the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%.

Institutional Investors Weigh In On NeuroMetrix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of NeuroMetrix by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 315,137 shares of the medical device company’s stock valued at $1,311,000 after buying an additional 19,667 shares in the last quarter. Renaissance Technologies LLC lifted its position in NeuroMetrix by 46.4% during the 2nd quarter. Renaissance Technologies LLC now owns 44,113 shares of the medical device company’s stock valued at $162,000 after acquiring an additional 13,985 shares during the period. Citadel Advisors LLC boosted its stake in NeuroMetrix by 44.3% during the third quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock worth $97,000 after acquiring an additional 10,652 shares in the last quarter. Virtu Financial LLC purchased a new stake in NeuroMetrix in the first quarter worth about $78,000. Finally, Northern Trust Corp bought a new position in shares of NeuroMetrix during the second quarter valued at approximately $41,000. 19.40% of the stock is owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.